Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis

Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani, Pier Luigi Canonico



Cost-Effectiveness; Peginterferon Beta-1a; Multiple Sclerosis

Full Text



  • Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur J Neurol 2005; 12 Suppl 1: 63-7;
  • Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010; 9: A387-94;
  • Multiple Sclerosis International Federation. Atlas of MS 2013. Available at (last accessed September 2018)
  • Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care 2013; 19(17 Suppl): s321-31
  • Iannazzo S, Santoni L, Saleri C, et al. Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management. Farmeconomia. Health economics and therapeutic pathways 2016; 17(Suppl 2): 13-36;
  • Iannazzo S, Iliza AC, Perrault L. Disease-modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies. Pharmacoeconomics 2018; 36: 189-204;
  • Peninsula Technology Assessment Group (PenTAG). The effectiveness and cost-effectiveness of natalizumab for multiple sclerosis: an evidence review of the submission from Biogen. Evidence Review Group Report commissioned by NHS R&D HTA Programme on behalf of: NICE, 2007. Available at (last accessed September 2018)
  • Calabresi PA, Deykin A, Arnold DL, et al. Analysis of 2-year clinical efficacy and safety of Peginterferon Beta-1a in patients with relapsing-remitting multiple sclerosis: data from the pivotal phase 3 ADVANCE study. American Academy of Neurology, 66th Annual Meeting. Philadelphia, 26 April-3 May 2014
  • Calabresi PA, Kieseier BC, Arnold DL, et al.; ADVANCE Study Investigators. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, doubleblind study. Lancet Neurol 2014; 13: 657-65;
  • Tolley K, Hutchinson M, You X, et al. A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other Injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One 2015: 1-21;
  • Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006; 7 Suppl 2: S45-54;
  • National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Available at (last accessed September 2018)
  • ISTAT. Consumer price index inflation to July 2018. Availabe at (last accessed September 2018)
  • Agenzia Italiana del Farmaco – AIFA. DETERMINA 31 maggio 2018. Rinegoziazione del medicinale per uso umano «Rebif», ai sensi dell’articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 866/2018). Italian Official Journal (Gazzetta Ufficiale) n. 145, June 25th, 2018
  • Battaglia M, Kobelt G, Ponzio M, et al.; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy. Mult Scler 2017; 23(2_suppl):104-116
  • Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler 2012; 18(2 Suppl): 29-34;
  • AIFA. Reference list for generic products (Lista di trasparenza). Update 09/08/2018. Available at (last accessed September 2018)
  • ISTAT. Mortality tables of the Italian general population. Year 2016. Available at (last accessed September 2018)


Abstract: 850 views
HTML: 154 views
PDF: 168 views


  • There are currently no refbacks.

© SEEd srl